{"entity":{"id":"decipher-prostate","kind":"drug","name":"Decipher Prostate","aka":[],"tldr":"A 22-gene test on the biopsy or surgical specimen that predicts spread and death, used to decide on surveillance or adding hormone therapy.","summary":"Decipher Prostate is a genomic classifier run on a whole-transcriptome array of biopsy or surgical tissue; a 22-gene random-forest model gives a score from 0 to 1 that predicts metastasis and prostate cancer death. It is used to choose between surveillance and treatment in localised disease and whether to add hormone therapy to radiation. It was validated on the NRG/RTOG 9601, 0126 and 9902 cohorts, carries NCCN level-1 evidence, and predicts benefit from ADT with radiation in some analyses. It is the basis of the Decipher-stratified trials NRG GU009 and GU010, which test whether intensifying or de-escalating treatment by score improves outcomes. It is complemented and challenged by ArteraAI Prostate, a digital pathology model that works from slide images alone. A newcomer can think of it as a gene test that estimates how aggressive a prostate tumour really is.","status":"established","asOf":"2026-09-06","links":[{"label":"Veracyte: Decipher Prostate genomic classifier","url":"https://www.veracyte.com/tests/decipher-prostate/"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["rna-seq","active-surveillance"],"targets":[],"drugs":["artera-ai-prostate"],"companies":["veracyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Gene-expression genomic classifier","mechanism":"Whole-transcriptome array; 22-gene random-forest genomic classifier score 0-1.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/decipher-prostate/","neighbours":{"cancer":[{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/"},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/"},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/"},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"drug":[{"id":"artera-ai-prostate","kind":"drug","name":"ArteraAI Prostate","route":"/drugs/artera-ai-prostate/"},{"id":"oncotype-dx-gps","kind":"drug","name":"Oncotype DX Genomic Prostate Score","route":"/drugs/oncotype-dx-gps/"},{"id":"prolaris","kind":"drug","name":"Prolaris","route":"/drugs/prolaris/"}],"company":[{"id":"veracyte","kind":"company","name":"Veracyte (Decipher)","route":"/companies/veracyte/"}]}}